Tiny ALS drug study measures body processing, not cure
NCT ID NCT04176224
First seen Jan 09, 2026 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This early-stage study looked at how a single dose of oral edaravone is processed by the body in 9 Japanese adults with ALS. The goal was to measure drug levels in blood and urine, not to test if it helps symptoms or slows the disease. Participants were aged 20-75 with definite or probable ALS. The study is complete and provides basic safety and drug behavior data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JAPANESE PATIENTS WITH ALS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.